Simplify Logo

Full-Time

Executive Director

Translational Sciences & Nonclinical Operations

Confirmed live in the last 24 hours

ReCode Therapeutics

ReCode Therapeutics

51-200 employees

Develops gene therapies for respiratory diseases

Biotechnology
Healthcare

Compensation Overview

$265k - $300kAnnually

Senior, Expert

Menlo Park, CA, USA

Category
Computational Biology
Genomics
Public Health
Biology & Biotech
Requirements
  • Advanced degree in life sciences or medicine (PhD/MD/PharmD).
  • 12+ years of experience in the biopharma industry in nonclinical development (toxicology, clinical pharmacology, bioanalytical sciences, or related discipline).
  • Strong scientific background and understanding of drug development, with specific expertise in nonclinical study design, preclinical CROs, data management systems, nonclinical study procedures, and statistical analysis methods.
  • Comprehensive knowledge of GLP regulations, including previous GLP experience in pharmaceutical or biotechnology industry or equivalent GXP experience.
  • Strong knowledge of global regulatory requirements, including FDA (CBER), EMA, MHRA, and other global regulatory authorities with prior experience drafting and supporting regulatory submissions/interactions.
  • Excellent communication and interpersonal skills with the ability to collaborate and work effectively in a cross-functional, fast-paced environment with an enterprise and growth-oriented mindset.
  • Strong leadership skills, high scientific integrity, and ability to positively influence cross-functional efforts to drive optimal outcomes for programs.
Responsibilities
  • Provide strategic direction and oversight for nonclinical aspects of ReCode’s development programs.
  • Drive successful completion of program requirements including but not limited to: Toxicology/Pathology, GLP Bioanalytical/DMPK, and Clinical Pharmacology deliverables to ensure robust and timely support for clinical development plans.
  • Assume responsibility for delivering high-quality data packages to regulatory authorities, to support early global scientific advice and program advancement through marketing approval.
  • Collaborate closely with cross-functional teams to align all nonclinical and translational deliverables with clinical development plans.
  • Develop contingency plans and backup scenarios to proactively mitigate unforeseen circumstances and minimize potential impact on timelines.
  • Partner closely with nonclinical operations, anticipating challenges and identifying creative solutions to ensure that the organization is well-prepared to address and/or mitigate.
  • Author, review, and preparation key nonclinical documents and associated deliverables for CTD/CTA modules, responding to health authority queries and contributing to the preparation of briefing documents for health authority interactions.
  • Oversee and mentor program/project translational lead(s) in a matrix environment.
  • Identify, retain, and manage consultants and external subject matter experts (SMEs) as needed to enhance and adjust functional strategies based on the latest scientific insights and regulatory requirements.
  • Maintain a proactive approach to adapt functional strategies to the evolving scientific and regulatory landscapes including monitoring the regulatory and competitive landscape to design base case and best-case scenarios for both traditional and expedited global approval pathways.
  • Foster collaborations and establish an external presence for ReCode as a leader of innovative nonclinical development of gene therapy and lipid nanoparticle-based therapeutics, by working with industry consortia, key opinion leaders, and external partners to stay at the forefront of developments in nonclinical and translational science strategies.
  • Act as a leader and steward of the 3Rs in development of nonclinical testing strategies.
  • Opportunity to take on full (end-to-end) project team leadership responsibilities for dedicated program(s) based on bandwidth, experience, aptitude, and interest.

ReCode Therapeutics develops gene therapy solutions aimed at treating complex respiratory diseases, specifically cystic fibrosis and primary ciliary dyskinesia. Their approach involves utilizing advanced drug development techniques to create therapies that can effectively target and restore function in patients suffering from these conditions. What sets ReCode apart from its competitors is its focus on overcoming challenges related to targeted delivery of therapies, which is crucial for the effectiveness of gene treatments. The company's goal is to enhance the quality of life for patients with unmet medical needs in respiratory health by advancing their therapies through rigorous clinical trials and eventually bringing them to market.

Company Stage

Series B

Total Funding

$521.8M

Headquarters

Dallas, Texas

Founded

2015

Growth & Insights
Headcount

6 month growth

1%

1 year growth

4%

2 year growth

52%
Simplify Jobs

Simplify's Take

What believers are saying

  • ReCode's recent $80 million Series A and additional $50 million Series B financing rounds indicate strong investor confidence and financial stability.
  • The appointment of experienced industry veterans like Dean J. Mitchell and John G. Matthews strengthens the company's leadership and clinical development capabilities.
  • Participation in high-profile conferences and strategic collaborations position ReCode as a thought leader in the genetic medicines space.

What critics are saying

  • The clinical-stage nature of ReCode's therapies means that they are still subject to the high risks and uncertainties of clinical trials.
  • The competitive landscape in genetic medicines and mRNA-based therapies is intense, with numerous well-funded competitors.

What makes ReCode Therapeutics unique

  • ReCode Therapeutics leverages its proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform for highly precise and targeted delivery of genetic medicines, setting it apart from competitors.
  • The company's focus on inhaled mRNA-based therapies for diseases like cystic fibrosis and primary ciliary dyskinesia addresses unmet needs in the respiratory disease market.
  • Strategic collaborations with leading gene editing companies like Intellia Therapeutics enhance ReCode's capabilities in developing novel genomic medicines.

Help us improve and share your feedback! Did you find this helpful?